Sonrotoclax + Zanubrutinib for Chronic Lymphocytic Leukemia

This trial examines whether adding a new drug, sonrotoclax, to an existing treatment, zanubrutinib, can improve outcomes for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Sonrotoclax may inhibit cancer growth by targeting a protein essential for cancer cell survival, while zanubrutinib blocks another protein that aids cancer cell growth. This trial targets individuals diagnosed with either CLL or SLL who have not received prior treatments and are experiencing significant symptoms like fatigue or unintentional weight loss. Participants will receive either zanubrutinib alone or in combination with sonrotoclax to determine which approach proves more effective. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants early access to potentially effective treatments.

The trial requires that you stop taking any strong CYP3A4/5 inhibitors or inducers at least 14 days before starting the study drug. Additionally, you must not be on active systemic anticoagulation with warfarin and should be off it for at least 5 half-lives before enrollment.

Previous studies have shown that the combination of sonrotoclax and zanubrutinib has a tolerable safety profile for people with chronic lymphocytic leukemia (CLL). Most patients can take the treatment without experiencing serious side effects. Research indicates that the combination is generally well-tolerated, with few patients needing to stop treatment due to side effects. Notably, there have been no reports of tumor lysis syndrome (TLS), a complication where cancer cells break down too quickly and overwhelm the body. This suggests that the treatment is manageable for patients. Overall, the safety data from earlier studies appear promising for those considering joining a trial.¹²³⁴⁵

Researchers are excited about the combination of zanubrutinib and sonrotoclax for treating Chronic Lymphocytic Leukemia (CLL) because it offers a novel approach by combining two targeted therapies. Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, which blocks signals that help cancer cells survive and multiply. The addition of sonrotoclax, a BCL-2 inhibitor, aims to enhance this effect by promoting cancer cell death. This dual targeting approach is different from standard treatments, like chemoimmunotherapy, and could potentially lead to deeper and longer-lasting remissions for patients with CLL.

Research has shown that combining sonrotoclax and zanubrutinib holds promise for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In one study, 98% of patients responded to this combination treatment, and 54% achieved a complete response, meaning no detectable cancer. After 48 weeks, 92% of patients had no measurable disease, indicating strong potential for controlling these conditions. This trial will compare the effectiveness of zanubrutinib alone, administered to participants in one arm, with the combination of zanubrutinib and sonrotoclax, given to participants in another arm. The combination has been well-tolerated, with few patients discontinuing due to side effects. These findings suggest that using sonrotoclax and zanubrutinib together might be more effective than using zanubrutinib alone.¹²³⁴⁵